Objective: To explore the predictive effect of baseline fasting C-peptide (FCP) on hypoglycemia risk, HbA1c reduction, and treatment satisfaction in Chinese T2DM individuals switching from premixed to basal insulin.

Methods: Post-hoc analysis of the single-arm, 16 weeks, phase IV OPTIMIZATION study. At 16 weeks, the study showed a mean reduction in HbA1c of 0.51% with basal insulin treatment after switching from premix. Study completers with baseline FCP testing (n=297) were stratified according to HbA1c <7.5% achievement or actual decrease at 16 weeks. In addition, hypoglycemia and patient feelings during treatment using DTSQ score were assessed. Different FCP thresholds were analyzed with Chi-square test and multivariate logistic regression analysis to test whether baseline FCP could be used to predict clinical results.

Results: When looking at efficacy alone, FCP >1.0 nmol/L could be used for predicting a higher probability to reach HbA1c <7.5% (OR=3.83, 95%CI 1.89, 7.73) and higher probability to achieve a HbA1c decrease >0.4% (OR=3.19, 95%CI 1.54, 6.59). By dividing participants using FCP dichotomy, similar results were obtained in people with FCP >0.59 nmol/L. When combined with overall hypoglycemia, both thresholds of FCP >1.0 nmol/L (OR=2.78, 95%CI 1.36, 5.68) and >0.59 nmol/L (OR=1.83, 95%CI 1.01, 3.30) predicted HbA1c <7.5% achievement without hypoglycemia. Similar results were also obtained for predicting both HbA1c<7.5% and better DTSQ score results.

Conclusion: Baseline fasting C-peptide could be used as a biomarker to predict greater HbA1c reduction, less hypoglycemia and better satisfaction in Chinese T2DM people switching from premixed to basal insulin.


W. Yang: Speaker’s Bureau; Self; AstraZeneca, Bayer Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck and Servier, Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis. P. Ruan: Employee; Self; Sanofi. X. Zhang: None. N. Cui: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.